Drugs / LP-003
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06604949 | Oct 2024 → Nov 2026 expected | chronic idiopathic urticaria | Longbio Pharma | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06294288 | Jul 2022 → Mar 2024 | chronic idiopathic urticaria | Longbio Pharma | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07148557 | Oct 2025 → May 2026 overdue | allergic disease | Longbio Pharma | Active not recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07816432 | Sep 2026 → Jul 2027 expected | food allergy | Longbio Pharma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07313917 | Jan 2026 → Feb 2027 expected | chronic rhinosinusitis | Longbio Pharma | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07342803 | Jan 2025 → Dec 2027 expected | allergic asthma | Longbio Pharma | Recruiting | No outcome recorded |
| Phase 2 | NCT06228560 | Jan 2024 → Apr 2025 | chronic urticaria | Longbio Pharma | Completed | No outcome recorded |
| Phase 2 | NCT06046391 | Jul → Oct 2023 | seasonal allergic rhinitis | Longbio Pharma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07291284 | Aug 2024 → Mar 2026 overdue | seasonal allergic rhinitis | Longbio Pharma | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07313917 ↗ |
| Action | Inhibit | “IgE blockade” NCT06046391 ↗ |
| Route | Subcutaneous | “received LP-003 subcutaneously for 8 weeks” NCT06046391 ↗ |